Radiotherapy for bone and soft tissue sarcomas

Sarcomas comprise a group of rare malignancies, accounting for approximately 1% of all adult cancers. Nevertheless, most of them are uniformly treated, regardless of histological subtype. The bone and soft tissue working group exploits efforts towards a more personalised approach.

Myxoid Liposarcoma Registry

Based upon the results obtained by the nicknamed “DOREMY” trial, NCT02106312, (JAMA Oncol. 2021 Jan 1;7(1):e205865) a global Registry has been initiated with the aim to collect real-world data on the treatment of this radiation sensitive rare subtype.

imagev6ppk.png

 

 

 

 

 

…

Myxoid Liposarcoma Registry

Based upon the results obtained by the nicknamed “DOREMY” trial, NCT02106312, (JAMA Oncol. 2021 Jan 1;7(1):e205865) a global Registry has been initiated with the aim to collect real-world data on the treatment of this radiation sensitive rare subtype.

imagev6ppk.png

 

 

 

 

 

 

 

 

 

 

Hypofractionation for soft tissue sarcomas

When preoperative radiotherapy is chosen to treat soft tissue sarcomas, currently a conventionally fractionated regimen of 25 x 2 Gy is applied.  In the nicknamed “SCOPES” trial (Short Course Of Preoperative radiotherapy in Extremity Sarcomas, NCT04425967) patients are randomized to undergo this conventional schedule or to by managed by a modestly hypofractionated schedule of 14 x 3 Gy. End points to be investigated are, postoperative wound complications, local control, overall survival, health related quality of life and cost effectiveness. This clinical trial is KWF approved; 13697.

Key publication

Team

  • Prof. dr. R.L.M. Haas
  • Dr. A.D.G. Krol
  • Dr. L.M. Wiltink